More articles about Diagnostics

Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.

In a first clinical tryout, University of Turku researchers have shown that their assay has sensitivity and specificity levels on par with those of laboratory ELISAs.

BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.

The company reported that it signed agreements for 337 instruments , while revenue-generating placements totaled  78 across the US, European, and Middle East regions.

TearLab sought a permanent injunction in Canada to keep I-Med's I-Pen Osmolarity System off the market, the company said.

The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.

An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.

The Class III Medical Device System License enables an early-risk assessment of the most common fetal genetic abnormalities in the first trimester of pregnancy.

The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.

The company offers a range of tumor profiling products including the OncoDeep solid tumor test and the OncoTrace liquid biopsy test.

Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.

The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood.

Three independent studies have shown that an α-synuclein assay technology detected early Parkinson's with high levels of sensitivity and specificity.

They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.

The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.

The immunoassay allows for the rapid detection of influenza types A and B antigens directly in nasal swab and nasopharyngeal swab specimens from symptomatic patients.

The company issued more than 1.8 million shares of its common stock to several of its trade creditors to erase debt that it owed them, Precipio said in an SEC document.

The five-year federal supply contract is for the company's Steripath Initial Specimen Diversion Device, which virtually eliminates blood culture contamination.

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

Currently available screening methods have not been shown to reduce mortality in the general population, USPSTF said.

Pages